Specific markers for metabolic syndrome
A metabolic syndrome and marker technology, which is applied in metabolic diseases, compound screening, drug combination, etc., can solve the problems of inapplicable routine screening, inapplicability, and high cost
Image
Examples
Embodiment
[0074] Total RNA was extracted using Ultraspec_RNA (Biotecx, Houston, TX) according to the manufacturer's protocol and treated with DNase for purification using the RNeasy Mini kit (Qiagen, Valencia, CA). Using T7-T24 primers, via SuperScript TM Double-stranded cDNA synthesis kit (LifeTechnology, Rockville, MD) synthesized double-stranded cDNA from 10 μg of total RNA. Double-stranded cDNA products were purified by phenol / chloroform / isoamyl alcohol extraction using phase-locked gels (Eppendorf, Westbury, NY). Using in vitro transcription (IVT) MEGAscript TM The double-stranded cDNA was further converted into cRNA by the T7 kit (Ambion, Austin, TX) and labeled with biotinyl nucleotide 1. In vitro transcripts were purified using the RNeasy Mini kit (Qiagen, Valencia, CA) and fragmented as described (Wodicka L, Dong H, Mittmann M, Ho MH, Lockhart DJ. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 1997; 15:1359-67). Hybridization of fragmented in...
PUM
Login to View More Abstract
Description
Claims
Application Information
- IPC
- G01N33/50; A61K31/16; A61K38/00; A61K38/16; A61K38/17; A61K39/395; A61K49/00; A61P3/04; A61P3/06; A61P3/10; A61P9/10; A61P9/12; C07K14/47; C07K16/18; C12N15/09; C12Q1/68; G01N33/15; G01N33/68
- CPC
- A61K31/16; A61K38/1709; A61K49/0004; A61P3/04; A61P3/06; A61P3/10; A61P9/00; A61P9/10
- Inventors
- 雅雷马·彼得·科汉; 詹姆斯·安德鲁·罗辛斯基
